Cell line · CVCL_8795
Papers36
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
1 to 20 of 36
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Docirbrutinib is a pan-mutant BTK inhibitor and inhibits B-cell receptor signaling in chronic lymphocytic leukemia cells in preclinical and early clinical investigations. | Blood Cancer J | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Sodium-myoinositol cotransporter-1 downstream of m6A methyltransferase WTAP exerts a potential carcinogenicity in diffuse large B-cell lymphoma progression. | J Transl Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Xenopus IgX informs engineering strategies of IgM and IgG hexamers. | Sci Adv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| B4 suppresses lymphoma progression by inhibiting fibroblast growth factor binding protein 1 through intrinsic apoptosis. | Front Pharmacol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. | Cancer Cell | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Response to Bruton's tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagy. | Cancer Cell | 2024 | Its Methods give the RRID and name the line | PubMed | |
| 4'-Ethynyl-2'-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress. | Mol Cancer Ther | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Plasmodium falciparum has evolved multiple mechanisms to hijack human immunoglobulin M. | Nat Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas. | Cancer Discov | 2023 | Its Methods give the RRID and name the line | PubMed | |
| IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. | Cancer Res Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| An Aged/Autoimmune B-cell Program Defines the Early Transformation of Extranodal Lymphomas. | Cancer Discov | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Role of Roflumilast Combined with ESHAP Chemotherapy in Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma. | Cancer Res Treat | 2022 | Its Methods give the RRID and name the line | PubMed | |
| ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors. | Cell Rep Med | 2021 | Its Methods give the RRID and name the line | PubMed | |
| IKKε and TBK1 in diffuse large B-cell lymphoma: A possible mechanism of action of an IKKε/TBK1 inhibitor to repress NF-κB and IL-10 signalling. | J Cell Mol Med | 2020 | Its Methods give the RRID and name the line | PubMed | |
| A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. | Cancer Cell | 2020 | Its Methods give the RRID and name the line | PubMed | |
| Next-generation characterization of the Cancer Cell Line Encyclopedia. | Nature | 2019 | Cellosaurus cites it | PubMed | |
| An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines. | Cancer Res | 2019 | Cellosaurus cites it | PubMed | |
| Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas. | Clin Cancer Res | 2018 | Cellosaurus cites it | PubMed | |
| B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell Malignancies. | Cell | 2018 | Its Methods give the RRID and name the line | PubMed | |
| Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma. | Oncotarget | 2018 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_8795/papers